Posts Tagged ‘oral semaglutide’
December 2, 2023 — Dozens of new obesity medicines are in the pipeline for clinical development. Some folks are especially interested in oral medicines that are small molecules. They’re looking for something that offers a sharp contrast with the complex peptide molecules (like semaglutide) given by injection, which are expensive and hard to make. One of the small, orally […]
May 23, 2023 — A pair of reports on Monday raised the possibility that we may soon have oral obesity meds that match the remarkable effectiveness of injections. One of these drugs is an oral formulation of semaglutide that’s already available at a much lower oral dose for diabetes under the brand name of Rybelsus. Novo Nordisk makes it. […]
March 27, 2023 — While Ozempic and Wegovy – two injectable forms of semaglutide – have been grabbing headlines, an oral tablet form – Rybelsus – has been quietly building momentum. Right now, it’s only approved for use in type 2 diabetes. But on Friday, Novo Nordisk announced results from the first phase 3 study of oral semaglutide for […]
June 8, 2021 — The mantra for the Wegovy brand of semaglutide just approved by FDA for obesity is clear enough – game changer. Great. Obesity is not a game, but health plans treat it like a 19th century game of hot potato: “Jack’s alive, and likely to live If he dies in your hand, you’ve a forfeit to […]
May 22, 2021 — Anyone following the news on progress with anti-obesity meds might have noticed a rising number of news reports about various “tides” for obesity. Liraglutide is already out there. So is setmelanotide. Semaglutide injection is under review at FDA and approval is possible as early as the middle of this year. Tirzepatide is advancing in clinical […]
September 21, 2019 — Holy grail? Game-changer? These superlatives were flying around as FDA approved Rybelsus – oral semaglutide – yesterday for type 2 diabetes. We don’t know about all that puffery, but it’s clear enough that this approval is a big deal. Oral semaglutide will be the first ever GLP-1 agonist in a pill. Up until now, taking […]